Patents by Inventor Jens Kaalby Thomsen

Jens Kaalby Thomsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HPYY(1-36) having a beta-homoarginine substitution at position 35
    Patent number: 10583172
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 35 of hPYY(1-36) substituted with beta-homoarginine and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: March 10, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff
  • Selective PYY compounds and uses thereof
    Patent number: 10246497
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: April 2, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen
  • SELECTIVE PYY COMPOUNDS AND USES THEREOF
    Publication number: 20160289283
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Application
    Filed: November 13, 2014
    Publication date: October 6, 2016
    Applicant: Novo Nordisk
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen
  • HPYY(1-36) Having a Beta-Homoarginine Substitution at Position 35
    Publication number: 20160263197
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 35 of hPYY(1-36) substituted with beta-homoarginine and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Application
    Filed: November 13, 2014
    Publication date: September 15, 2016
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff
  • Selective PYY compounds and uses thereof
    Patent number: 9085637
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: July 21, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen
  • Selective PYY compounds and uses thereof
    Publication number: 20150152150
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Application
    Filed: November 13, 2014
    Publication date: June 4, 2015
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen
  • Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide
    Patent number: 8937042
    Abstract: Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: January 20, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Anne Plum, Dorte Bjerre Steensgaard, Jens Kaalby Thomsen, Morten Schlein, Anne Sofie Kajær Markussen, Christian Poulsen
  • LONG-ACTING Y2 RECEPTOR AGONISTS
    Publication number: 20130096055
    Abstract: The present invention relates to PYY derivatives comprising a serum albumin binding side chain, wherein said derivative has a half-life of at least 7 hours as determined by Assay (IV) described herein as well as compositions comprising said derivative and its use in therapy.
    Type: Application
    Filed: November 15, 2010
    Publication date: April 18, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Jacob Kofoed, Lars Ynddal, Soeren Oestergaard, Rasmus Joergensen, Flemming Sejer Nielsen, Cecilia Nilsson, Jens Kaalby Thomsen
  • Pharmaceutical Compositions Comprising GLP-1 Peptides or Extendin-4 and a Basal Insulin Peptide
    Publication number: 20110152185
    Abstract: Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules.
    Type: Application
    Filed: November 14, 2008
    Publication date: June 23, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Anne Plum, Dorte Bjerre Steensgaard, Jens Kaalby Thomsen, Morten Schlein, Anne Sofie Kajaer Markussen, Christian Poulsen